Integrated Approaches Revealed the Therapeutic Mechanisms of Zuojin Pill Against Gastric Mucosa Injury in a Rat Model with Chronic Atrophic Gastritis
DOI: https://doi.org/10.2147/dddt.s454758
IF: 4.3188
2024-05-18
Drug Design Development and Therapy
Abstract:Lisheng Chen, 1, 2 Tingting He, 3 Ruilin Wang, 3 Honghong Liu, 4 Xin Wang, 1, 2 Haotian Li, 2 Manyi Jing, 2 Xuelin Zhou, 5 Shizhang Wei, 6 Wenjun Zou, 1 Yanling Zhao 1, 2 1 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 2 Department of Pharmacy Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China; 3 Division of Integrative Medicine, The Fifth Medical Center of General Hospital of PLA, Beijing, People's Republic of China; 4 Integrated TCM & Western Medicine Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China; 5 Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, People's Republic of China; 6 Department of Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University, Beijing, People's Republic of China Correspondence: Yanling Zhao, Department of Pharmacy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China, Email Wenjun Zou, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China, Email Background: The Zuojin Pill (ZJP) is widely used for treating chronic atrophic gastritis (CAG) in clinical practice, effectively ameliorating symptoms such as vomiting, pain, and abdominal distension in patients. However, the underlying mechanisms of ZJP in treating CAG has not been fully elucidated. Purpose: This study aimed to clarify the characteristic function of ZJP in the treatment of CAG and its potential mechanism. Methods: The CAG model was established by alternant administrations of ammonia solution and sodium deoxycholate, as well as an irregular diet. Therapeutic effects of ZJP on body weight, serum biochemical indexes and general condition were analyzed. HE staining and AB-PAS staining were analyzed to characterize the mucosal injury and the thickness of gastric mucosa. Furthermore, network pharmacology and molecular docking were used to predict the regulatory mechanism and main active components of ZJP in CAG treatment. RT-PCR, immunohistochemistry, immunofluorescence and Western blotting were used to measure the expression levels of apoptosis-related proteins, gastric mucosal barrier-associated proteins and PI3K/Akt signaling pathway proteins. Results: The results demonstrated that ZJP significantly improved the general state of CAG rats, alleviated weight loss and gastric histological damage and reduced the serum biochemical indicators. Network pharmacology and molecular docking found that ZJP in treating CAG by inhibiting inflammation, suppressing apoptosis, and protecting the gastric mucosal barrier via the PI3K/Akt signaling pathway. Further experiments confirmed that ZJP obviously modulated the expression of key proteins involved in gastric mucosal cell apoptosis, such as Bax, Bad, Apaf-1, cleaved-caspase-3, cleaved-caspase-9, Cytochrome C, Bcl-2, and Bcl-xl. Moreover, ZJP significantly reversed the protein expression of Occludin, ZO-1, Claudin-4 and E-cadherin. Conclusion: Our study revealed that ZJP treats CAG by inhibiting the PI3K/Akt signaling pathway. This research provided a scientific basis for the rational use of ZJP in clinical practice. Keywords: Zuojin Pill, chronic atrophic gastritis, network pharmacology, molecular docking, PI3K/Akt signaling pathway Chronic atrophic gastritis (CAG) is a gastric disease with pathological characteristics of reduced gastric acid secretion, atrophic gastric mucosa and metaplasia of intestine epithelium. 1,2 CAG is considered a key precancerous lesion in gastric cancer, which is the third leading cause of cancer death reported in the global cancer statistics for 2018. 3 Previous studies have shown that CAG is caused by a combination of factors, including helicobacter pylori infection, inadequate immune regulation and impaired energy metabolism, and that its pathogenesis is related to oxidative stress, inflammation, endothelial and mucosal dysfunction. 4,5 The current clinical treatment of CAG relies mainly on the agents used for gastric mucosal protection and symptom relief, vitamin C supplementation and proton pump inhibitors, which limit their clinical application due to their long course, aggressiveness and side effects. 6,7 Therefore, there is an urgent need for complementary and alternative treatments for CAG. Traditional Chinese medicine (TCM) has unique advantages in the treatme -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal